Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Jul 16, 2023 10:01pm
320 Views
Post# 35543517

RE:RE:RE:RE:What is ONCY worth, when?

RE:RE:RE:RE:What is ONCY worth, when?I agree Buyout is only thing that makes sense at this point.<br /> A P3 in Breast, P3 in Pancreatic,&nbsp; more than likely a P3 in metastatic colorectal cancer as well. I&#39;m 95% sure that there will be a P3 in Colorectal cancer. There&#39;s always that 5%.&nbsp; though. Anal cancer I&#39;m not sure about.&nbsp;&nbsp;<br /> Then there&#39;s a CAR-T deal potential. Dr. Vile at Mayo is working on a project being funded by National Cancer Institute that will have protocols in place for CAR-T and Virus therapy that will take this to the next level.&nbsp;<br /> <br /> Then we have Adlai Nortye deal P3 for breast, and who knows they may be looking at P3 pancreatic and colorectal as well now?<br /> <br /> Anyway it way too much for a small biotech like ONC to take on

<< Previous
Bullboard Posts
Next >>